| All prices are in Canadian dollars | |
|---|---|
| Limited special offer: | $64.95/bottle |
| 5 to 9 bottles: | $62.95/bottle |
| 10 or more bottles: | $59.95/bottle |
| Free shipping for 5 bottles or more | |
Research Articles on BioBran / MGN-3
Research articles on BioBran / MGN-3 - manufactured and now being distributed in the expanding US market by Daiwa Pharmaceutical Co., Ltd. - have been published successively in three US peer-reviewed journals. All the research has been carried forward by research groups headed by Dr. M. Ghoneum (Professor of UCLA/Drew University of Medicine and Science), who is one of the developers of BioBran and who has been continuing clinical studies and other research on the product. Their research results have been interpreted as evidence for a new clinical use of the product, thereby attracting attention from various quarters.
The article entitled MGN-3/Biobran, modified arabinoxylan from rice bran, sensitize human breast cancer cells to chemotherapeutic agent, daunorubicin
was published in Cancer Detection and Prevention (2007). The following is a summary of that article. Our previous studies demonstrated that MGN-3, known to be a potent biological response modifier (BRM), sensitizes human leukemia cells to death receptor (CD95)-induced apoptosis. In this study, we evaluated the chemosensitizing activity of MGN-3 against human breast cancer cells (BCCs) in vitro and determined cancer cell survival by MTT assay and drug accumulation by flow cytometry.
The results revealed that treatment with MGN-3 increased the susceptibility of BCCs to DNR (5.5-fold for MCF-7 cells and 2.5-fold for HCC70 cells) as compared to BCCs treated with DNR alone. The sensitizing effect of MGN-3 was associated with an increased accumulation of DNR in the cancer cells. Our data demonstrate that MGN-3 is an effective chemosensitizer and may represent a potential novel adjuvant for the treatment of breast cancer.
The article entitled In Vivo Tumor Inhibitory Effects of Nutritional Rice Bran Supplement MGN-3/Biobran on Ehrlich Carcinoma-Bearing Mice
was published in Nutrition and Cancer (2008). The following is a summary of that article.
Swiss albino mice were inoculated intramuscularly in the right thigh with Ehrlich ascites carcinoma (EAC) cells. On day 8 following the inoculation, mice bearing solid Ehrlich carcinoma tumors (SEC) were treated with MGN-3 via intraperitoneal injection in order to examine tumor growth, cytokine production, and the apoptotic effects of MGN-3. Animals treated with MGN-3 had significantly smaller tumor volumes (63.27%) and tumor weights (45.2%) as compared with the controls (P < 0.01).
The mechanisms by which MGN-3 exerts its antitumor effect appear to involve its ability to induce apoptosis and immune modulation. Flow cytometry and histopathological examination demonstrated that MGN-3 induced a 1.8-fold increase in the percentage of apoptotic SEC cells. No adverse effects due to MGN-3 treatment were observed; all animals displayed normal feeding, drinking, and life activity patterns.
These data suggest the potential clinical utility of MGN-3 for the treatment of solid cancers.
The article entitled Modified Arabinoxylan rice bran (MGN-3/BioBran) enhances intracellular killing of microbes by human phagocytic cells in vitro
was published in the International Journal of Immunopathology and Pharmacology (2008). The following is a summary of that article.
Our earlier study demonstrated that MGN-3/BioBran activates murine peritoneal macrophages and macrophage cell lines.
In this study, we investigated whether MGN-3 can upregulate the phagocytic activity of human phagocytes in peripheral blood to phagocytize Escherichia coli (E. coli), trigger an oxidative burst, and produce cytokines. Phagocytic cells were prestained with dichlorofluorescein diacetate dye and were incubated with phycoerythrin-stained E. coli in the presence or absence of MGN-3. Phagocytosis and oxidative burst were assessed by flow cytometry. The results revealed that treatment with MGN-3 was associated with an increased oxidative burst and an enhanced phagocytosis of E. coli by neutrophils and monocytes. In addition, it caused a significant induction of cytokines (TNF-alpha, IL-8, and IL-10); this effect was detected at 1microg/mL of BioBran and increased in a dose-dependent manner. Notably, MGN-3 alone had no effect on the growth of 31 strains of bacteria, suggesting that MGN-3 can modulate phagocytic cellular function.
These findings indicate the potential applications of BioBran in the treatment of infections in the elderly and in immunocompromised patients.